Find a clinical trial

FindClinicalTrial

If you have questions about clinical trials or want help finding the right one for you, contact our:

Patient Engagement Center Phone: 844-552-2734

This is a preliminary search of all open and enrolling clinical trials across our regions and affiliate organizations that have sponsors' permission to publish to this website.

Please use the filtering options in the right column to refine your search. Otherwise ALL open and enrolling clinical trials will display below.

Viewing Page 3 of 27 | Showing Results 11 - 15 of 135

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2–) Breast Cancer (KEYNOTE-756)

Inclusion Criteria:•Has a localized invasive breast ductal adenocarcinoma, confirmed by the local pathologist, that includes either T1c-T2 (tumor...

Ying Zhuo, M.D.
  • Kadlec Clinic Hematology and Oncology
  • Kadlec Research

VERONICA A Phase II, Multicenter, Randomized study to compare the efficacy of Venetoclax plus Fulvestrant versus Fulvestrant in women with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer who experienced disease recurrence or progression during or after CDK4/6 inhibitor therapy.

This is a Phase II, multicenter, open-label, randomized study to compare the efficacy of venetoclax in combination with fulvestrant compared with...

Ajay Kundra, M.D.
  • Providence Regional Cancer Partnership - Everett

A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009)

PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors.Inclusion...

Erin Ellis, M.D.
  • Swedish Medical Center

VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Key secondary objectives are an arm-to-arm comparison of the following:Radiographic progression-free survival (rPFS)Response Evaluation Criteria in...

Song Zhao, M.D.
  • Swedish Medical Center
Viewing Page 3 of 27 | Showing Results 11 - 15 of 135